津力达颗粒联合德谷胰岛素利拉鲁肽注射液治疗血糖控制不佳2型糖尿病的临床疗效

Clinical efficacy of Jinlida granule combined with Degu insulin Liraglutide injection in the treatment of T2DM with poor glycemic control

摘要:

目的 探讨津力达颗粒联合德谷胰岛素利拉鲁肽注射液治疗血糖控制不佳的2型糖尿病（T2DM）的临床疗效。方法 前瞻性选取2022年2月—2023年6月山东中医药大学附属医院收治的68例血糖控制不佳的T2DM患者，按照随机数字表法分为研究组与对照组，每组34例。对照组给予常规治疗联合德谷胰岛素利拉鲁肽注射液；研究组在对照组基础上给予津力达颗粒，两组治疗8周后观察疗效。对比两组治疗前后中医证候评分、血糖代谢、胰岛功能、血脂代谢、外周血细胞因子的变化及治疗后不良反应情况。结果 研究组治疗前后的多饮多尿、消谷易饥、倦怠乏力、自汗盗汗、五心烦热中医证候评分差值均高于对照组（P <0.05）。研究组治疗前后的空腹血糖、餐后2 h血糖、糖化血红蛋白差值均高于对照组（P <0.05）。研究组治疗前后的胰岛素抵抗指数、胰岛β-细胞功能指数差值均高于对照组（P <0.05）。研究组治疗前后的甘油三酯、总胆固醇、低密度脂蛋白胆固醇差值均高于对照组（P <0.05）。研究组治疗前后的网膜素-1、单核细胞趋化蛋白-1、胰岛素样生长因子差值均高于对照组（P <0.05）。两组不良反应发生率比较，差异无统计学意义（P >0.05）。结论 津力达颗粒联合德谷胰岛素利拉鲁肽注射液治疗血糖控制不佳的T2DM可明显改善患者临床症状及糖脂代谢情况，并改善胰岛功能、抑制胰岛素抵抗，调控外周血因子分泌，且安全性良好。

Abstract:

Objective To investigate the efficacy of Jindali granules combined with Degu insulin Liraglutide injection in treating poorly controlled type 2 diabetes mellitus (T2DM).Methods A prospective study was conducted with 68 T2DM patients with poor glycemic control, admitted to the Affiliated Hospital of Shandong University of traditional Chinese medicine from February 2022 to June 2023. Patients were randomly assigned to either the study group or the control group, with 34 patients in each group. The control group received conventional treatment combined with Degu insulin Liraglutide injection, while the study group received Jindali granules in addition to the treatment provided to the control group. Treatment lasted for 8 weeks, and outcomes were assessed based on changes in traditional Chinese medicine (TCM) syndrome scores, blood glucose metabolism, pancreatic function, lipid metabolism, peripheral blood cytokines, and adverse reactions.Results The study group showed greater improvements in TCM syndrome scores for polydipsia, polyuria, excessive hunger, fatigue, and night sweating compared to the control group (P < 0.05). Significant improvements in fasting blood glucose, postprandial 2-hour blood glucose, and glycated hemoglobin were also observed in the study group (P < 0.05). Additionally, the study group demonstrated greater improvements in insulin resistance index and β-cell function index compared to the control group (P < 0.05). Changes in triglycerides, total cholesterol, and low-density lipoprotein cholesterol were more favorable in the study group (P < 0.05). The study group also showed greater improvements in serum levels of retinol binding protein-1, monocyte chemoattractant protein-1, and insulin-like growth factor (P < 0.05). There were no significant differences in the incidence of adverse reactions between the two groups (P > 0.05).Conclusion Jindali granules combined with Degu insulin Liraglutide injection significantly improves symptoms and glycemic and lipid metabolism in patients with poorly controlled T2DM, enhances pancreatic function, reduces insulin resistance, and modulates peripheral blood cytokine levels, with good safety.